<?xml version='1.0' encoding='utf-8'?>
<pmc-articleset xmlns:ns0="http://www.w3.org/1999/xlink">
  <article id="jcsm12828" xml:lang="en" article-type="research-article" dtd-version="1.4">
    <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
      <restricted-by>pmc</restricted-by>
    </processing-meta>
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">J Cachexia Sarcopenia Muscle</journal-id>
        <journal-id journal-id-type="iso-abbrev">J Cachexia Sarcopenia Muscle</journal-id>
        <journal-id journal-id-type="pmc-domain-id">1721</journal-id>
        <journal-id journal-id-type="pmc-domain">cachex</journal-id>
        <journal-id journal-id-type="publisher-id">JCSM</journal-id>
        <journal-title-group>
          <journal-title>Journal of Cachexia, Sarcopenia and Muscle</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">2190-5991</issn>
        <issn pub-type="epub">2190-6009</issn>
        <publisher>
          <publisher-name>Wiley</publisher-name>
        </publisher>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC8718021</article-id>
        <article-id pub-id-type="pmcid-ver">PMC8718021.1</article-id>
        <article-id pub-id-type="pmcaid">8718021</article-id>
        <article-id pub-id-type="pmcaiid">8718021</article-id>
        <article-id pub-id-type="pmid">34658160</article-id>
        <article-id pub-id-type="doi">10.1002/jcsm.12828</article-id>
        <article-id pub-id-type="publisher-id">JCSM12828</article-id>
        <article-id pub-id-type="other">JCSM-D-21-00011</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="overline">
            <subject>Original Article</subject>
          </subj-group>
          <subj-group subj-group-type="heading">
            <subject>Original Articles</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Effects and tolerability of exercise therapy modality on cardiorespiratory fitness in lung cancer: a randomized controlled trial</article-title>
          <alt-title alt-title-type="right-running-head">Exercise therapy and lung cancer</alt-title>
          <alt-title alt-title-type="left-running-head">J.M. Scott <italic toggle="yes">et al</italic>.</alt-title>
        </title-group>
        <contrib-group>
          <contrib id="jcsm12828-cr-0001" contrib-type="author">
            <name name-style="western">
              <surname>Scott</surname>
              <given-names initials="JM">Jessica M.</given-names>
            </name>
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4845-5800</contrib-id>
            <xref rid="jcsm12828-aff-0001" ref-type="aff">
              <sup>1</sup>
            </xref>
            <xref rid="jcsm12828-aff-0002" ref-type="aff">
              <sup>2</sup>
            </xref>
          </contrib>
          <contrib id="jcsm12828-cr-0002" contrib-type="author">
            <name name-style="western">
              <surname>Thomas</surname>
              <given-names initials="SM">Samantha M.</given-names>
            </name>
            <xref rid="jcsm12828-aff-0003" ref-type="aff">
              <sup>3</sup>
            </xref>
          </contrib>
          <contrib id="jcsm12828-cr-0003" contrib-type="author">
            <name name-style="western">
              <surname>Herndon</surname>
              <given-names initials="JE">James E.</given-names>
              <suffix>II</suffix>
            </name>
            <xref rid="jcsm12828-aff-0003" ref-type="aff">
              <sup>3</sup>
            </xref>
          </contrib>
          <contrib id="jcsm12828-cr-0004" contrib-type="author">
            <name name-style="western">
              <surname>Douglas</surname>
              <given-names initials="PS">Pamela S.</given-names>
            </name>
            <xref rid="jcsm12828-aff-0003" ref-type="aff">
              <sup>3</sup>
            </xref>
          </contrib>
          <contrib id="jcsm12828-cr-0005" contrib-type="author">
            <name name-style="western">
              <surname>Yu</surname>
              <given-names initials="AF">Anthony F.</given-names>
            </name>
            <xref rid="jcsm12828-aff-0001" ref-type="aff">
              <sup>1</sup>
            </xref>
            <xref rid="jcsm12828-aff-0002" ref-type="aff">
              <sup>2</sup>
            </xref>
          </contrib>
          <contrib id="jcsm12828-cr-0006" contrib-type="author">
            <name name-style="western">
              <surname>Rusch</surname>
              <given-names initials="V">Valerie</given-names>
            </name>
            <xref rid="jcsm12828-aff-0001" ref-type="aff">
              <sup>1</sup>
            </xref>
            <xref rid="jcsm12828-aff-0002" ref-type="aff">
              <sup>2</sup>
            </xref>
          </contrib>
          <contrib id="jcsm12828-cr-0007" contrib-type="author">
            <name name-style="western">
              <surname>Huang</surname>
              <given-names initials="J">James</given-names>
            </name>
            <xref rid="jcsm12828-aff-0001" ref-type="aff">
              <sup>1</sup>
            </xref>
            <xref rid="jcsm12828-aff-0002" ref-type="aff">
              <sup>2</sup>
            </xref>
          </contrib>
          <contrib id="jcsm12828-cr-0008" contrib-type="author">
            <name name-style="western">
              <surname>Capaci</surname>
              <given-names initials="C">Catherine</given-names>
            </name>
            <xref rid="jcsm12828-aff-0001" ref-type="aff">
              <sup>1</sup>
            </xref>
          </contrib>
          <contrib id="jcsm12828-cr-0009" contrib-type="author">
            <name name-style="western">
              <surname>Harrison</surname>
              <given-names initials="JN">Jenna N.</given-names>
            </name>
            <xref rid="jcsm12828-aff-0001" ref-type="aff">
              <sup>1</sup>
            </xref>
          </contrib>
          <contrib id="jcsm12828-cr-0010" contrib-type="author">
            <name name-style="western">
              <surname>Stoeckel</surname>
              <given-names initials="KJ">Kurtis J.</given-names>
            </name>
            <xref rid="jcsm12828-aff-0001" ref-type="aff">
              <sup>1</sup>
            </xref>
          </contrib>
          <contrib id="jcsm12828-cr-0011" contrib-type="author">
            <name name-style="western">
              <surname>Nilsen</surname>
              <given-names initials="T">Tormod</given-names>
            </name>
            <xref rid="jcsm12828-aff-0004" ref-type="aff">
              <sup>4</sup>
            </xref>
          </contrib>
          <contrib id="jcsm12828-cr-0012" contrib-type="author">
            <name name-style="western">
              <surname>Edvardsen</surname>
              <given-names initials="E">Elisabeth</given-names>
            </name>
            <xref rid="jcsm12828-aff-0004" ref-type="aff">
              <sup>4</sup>
            </xref>
          </contrib>
          <contrib id="jcsm12828-cr-0013" contrib-type="author">
            <name name-style="western">
              <surname>Michalski</surname>
              <given-names initials="MG">Meghan G.</given-names>
            </name>
            <xref rid="jcsm12828-aff-0001" ref-type="aff">
              <sup>1</sup>
            </xref>
          </contrib>
          <contrib id="jcsm12828-cr-0014" contrib-type="author">
            <name name-style="western">
              <surname>Eves</surname>
              <given-names initials="ND">Neil D.</given-names>
            </name>
            <xref rid="jcsm12828-aff-0005" ref-type="aff">
              <sup>5</sup>
            </xref>
          </contrib>
          <contrib id="jcsm12828-cr-0015" contrib-type="author" corresp="yes">
            <name name-style="western">
              <surname>Jones</surname>
              <given-names initials="LW">Lee W.</given-names>
            </name>
            <xref rid="jcsm12828-aff-0001" ref-type="aff">
              <sup>1</sup>
            </xref>
            <xref rid="jcsm12828-aff-0002" ref-type="aff">
              <sup>2</sup>
            </xref>
            <address>
              <email>jonesl3@mskcc.org</email>
            </address>
          </contrib>
        </contrib-group>
        <aff id="jcsm12828-aff-0001" content-type="private-address">
          <label>
            <sup>1</sup>
          </label>
          <institution>Memorial Sloan‐Kettering Cancer Center</institution>
          <city>New York</city>
          <named-content content-type="country-part">NY</named-content>
          <country country="US">USA</country>
        </aff>
        <aff id="jcsm12828-aff-0002" content-type="private-address">
          <label>
            <sup>2</sup>
          </label>
          <institution>Weill Cornell Medical College</institution>
          <city>New York</city>
          <named-content content-type="country-part">NY</named-content>
          <country country="US">USA</country>
        </aff>
        <aff id="jcsm12828-aff-0003" content-type="private-address">
          <label>
            <sup>3</sup>
          </label>
          <institution>Duke University Medical Center</institution>
          <city>Durham</city>
          <named-content content-type="country-part">NC</named-content>
          <country country="US">USA</country>
        </aff>
        <aff id="jcsm12828-aff-0004">
          <label>
            <sup>4</sup>
          </label>
          <named-content content-type="organisation-division">Department of Sports Medicine</named-content>
          <institution>Norwegian School of Sport Sciences</institution>
          <city>Oslo</city>
          <country country="NO">Norway</country>
        </aff>
        <aff id="jcsm12828-aff-0005" content-type="private-address">
          <label>
            <sup>5</sup>
          </label>
          <institution>University of British Columbia</institution>
          <city>Kelowna</city>
          <named-content content-type="country-part">BC</named-content>
          <country country="CA">Canada</country>
        </aff>
        <author-notes>
          <corresp id="correspondenceTo">
            <label>*</label>
Correspondence to: Lee W. Jones, Department of Medicine, Memorial Sloan‐Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. Email: <email>jonesl3@mskcc.org</email>
            <break />
          </corresp>
        </author-notes>
        <pub-date pub-type="epub">
          <day>17</day>
          <month>10</month>
          <year>2021</year>
        </pub-date>
        <pub-date pub-type="ppub">
          <month>12</month>
          <year>2021</year>
        </pub-date>
        <volume>12</volume>
        <issue seq="100">6</issue>
        <issue-id pub-id-type="pmc-issue-id">396828</issue-id>
        <issue-id pub-id-type="doi">10.1002/jcsm.v12.6</issue-id>
        <fpage>1456</fpage>
        <lpage>1465</lpage>
        <self-uri content-type="pmc-pdf" ns0:href="JCSM-12-1456.pdf" />
        <self-uri content-type="pdf" ns0:href="file:JCSM-12-1456.pdf" />
        <abstract>
          <title>Abstract</title>
          <sec id="jcsm12828-sec-0001">
            <title>Background</title>
            <p>Poor cardiorespiratory fitness (CRF) is a cardinal feature of post‐treatment primary lung cancer. The most effective exercise therapy regimen to improve CRF has not been determined.</p>
          </sec>
          <sec id="jcsm12828-sec-0002">
            <title>Methods</title>
            <p>In this parallel‐group factorial randomized controlled trial, lung cancer survivors with poor CRF (below age–sex sedentary values) were randomly allocated to receive 48 consecutive supervised sessions thrice weekly of (i) aerobic training (AT)—cycle ergometry at 55% to &gt;95% of peak oxygen consumption (VO<sub>2</sub>peak); (ii) resistance training (RT)—lower and upper extremity exercises at 50–85% of maximal strength; (iii) combination training (CT)—AT plus RT; or (iv) stretching attention control (AC) for 16 weeks. The primary endpoint was change in CRF (VO<sub>2</sub>peak, mL O<sub>2</sub>·kg<sup>−1</sup>·min<sup>−1</sup>). Secondary endpoints were body composition, muscle strength, patient‐reported outcomes, tolerability (relative dose intensity of exercise), and safety. Analysis of covariance determined change in primary and secondary endpoints from baseline to post‐intervention (Week 17) with adjustment for baseline values of the endpoint and other relevant clinical covariates.</p>
          </sec>
          <sec id="jcsm12828-sec-0003">
            <title>Results</title>
            <p>Ninety patients (65 ± 9 years; 66% female) were randomized (AT, <italic toggle="yes">n</italic> = 24; RT, <italic toggle="yes">n</italic> = 23; CT, <italic toggle="yes">n</italic> = 20; and AC, <italic toggle="yes">n</italic> = 23) of the planned <italic toggle="yes">n</italic> = 160. No serious adverse events were observed. For the overall cohort, the lost‐to‐follow‐up rate was 10%. Mean attendance was ≥75% in all groups. In intention‐to‐treat analysis, VO<sub>2</sub>peak increased 1.1 mL O<sub>2</sub>·kg<sup>−1</sup>·min<sup>−1</sup> [95% confidence interval (CI): 0.0, 2.2, <italic toggle="yes">P</italic> = 0.04] and 1.4 mL O<sub>2</sub>·kg<sup>−1</sup>·min<sup>−1</sup> (95% CI: 0.2, 2.5, <italic toggle="yes">P</italic> = 0.02) in AT and CT, respectively, compared with AC. There was no difference in VO<sub>2</sub>peak change between RT and AC (−0.1 mL O<sub>2</sub>·kg<sup>−1</sup>·min<sup>−1</sup>, 95% CI: −1.2, 1.0, <italic toggle="yes">P</italic> = 0.88). Favourable improvements in maximal strength and body composition were observed in RT and CT groups compared with AT and AC groups (<italic toggle="yes">P</italic>s &lt; 0.05). No between‐group changes were observed for any patient‐reported outcomes. Relative dose intensity of exercise was lower in RT and CT compared with AT (<italic toggle="yes">P</italic>s &lt; 0.05).</p>
          </sec>
          <sec id="jcsm12828-sec-0004">
            <title>Conclusions</title>
            <p>In the context of a smaller than planned sample size, AT and CT significantly improved VO<sub>2</sub>peak in lung cancer survivors; however, the tolerability‐to‐benefit ratio was superior for AT and hence may be the preferred modality to target impaired CRF in post‐treatment lung cancer survivors.</p>
          </sec>
        </abstract>
        <kwd-group kwd-group-type="author-generated">
          <kwd id="jcsm12828-kwd-0001">Aerobic training</kwd>
          <kwd id="jcsm12828-kwd-0002">Resistance training</kwd>
          <kwd id="jcsm12828-kwd-0003">Combination training</kwd>
          <kwd id="jcsm12828-kwd-0004">Exercise capacity</kwd>
          <kwd id="jcsm12828-kwd-0005">Cancer survivorship</kwd>
        </kwd-group>
        <funding-group>
          <award-group id="funding-0001">
            <funding-source>
              <institution-wrap>
                <institution>Memorial Sloan‐Kettering Cancer Center
</institution>
                <institution-id institution-id-type="doi">10.13039/100007052</institution-id>
              </institution-wrap>
            </funding-source>
            <award-id>P30 CA008748</award-id>
          </award-group>
          <award-group id="funding-0002">
            <funding-source>AKTIV Against Cancer</funding-source>
          </award-group>
          <award-group id="funding-0003">
            <funding-source>
              <institution-wrap>
                <institution>National Institutes of Health
</institution>
                <institution-id institution-id-type="doi">10.13039/100000002</institution-id>
              </institution-wrap>
            </funding-source>
            <award-id>R01‐CA138624</award-id>
          </award-group>
        </funding-group>
        <counts>
          <fig-count count="2" />
          <table-count count="3" />
          <page-count count="10" />
          <word-count count="4387" />
        </counts>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-license-ref</meta-name>
            <meta-value>CC BY-NC-ND</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>source-schema-version-number</meta-name>
            <meta-value>2.0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>cover-date</meta-name>
            <meta-value>December 2021</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>details-of-publishers-convertor</meta-name>
            <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.7.0 mode:remove_FC converted:30.12.2021</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
      <notes>
        <p content-type="self-citation">
          <mixed-citation publication-type="journal" id="jcsm12828-cit-0001">
            <string-name name-style="western">
              <surname>Scott</surname>
              <given-names>J. M.</given-names>
            </string-name>, <string-name name-style="western">
              <surname>Thomas</surname>
              <given-names>S. M.</given-names>
            </string-name>, <string-name name-style="western">
              <surname>Herndon</surname>
              <suffix>II</suffix>
              <given-names>J. E.</given-names>
            </string-name>, <string-name name-style="western">
              <surname>Douglas</surname>
              <given-names>P. S.</given-names>
            </string-name>, <string-name name-style="western">
              <surname>Yu</surname>
              <given-names>A. F.</given-names>
            </string-name>, <string-name name-style="western">
              <surname>Rusch</surname>
              <given-names>V.</given-names>
            </string-name>, <string-name name-style="western">
              <surname>Huang</surname>
              <given-names>J.</given-names>
            </string-name>, <string-name name-style="western">
              <surname>Capaci</surname>
              <given-names>C.</given-names>
            </string-name>, <string-name name-style="western">
              <surname>Harrison</surname>
              <given-names>J. N.</given-names>
            </string-name>, <string-name name-style="western">
              <surname>Stoeckel</surname>
              <given-names>K. J.</given-names>
            </string-name>, <string-name name-style="western">
              <surname>Nilsen</surname>
              <given-names>T.</given-names>
            </string-name>, <string-name name-style="western">
              <surname>Edvardsen</surname>
              <given-names>E.</given-names>
            </string-name>, <string-name name-style="western">
              <surname>Michalski</surname>
              <given-names>M. G.</given-names>
            </string-name>, <string-name name-style="western">
              <surname>Eves</surname>
              <given-names>N. D.</given-names>
            </string-name>, and <string-name name-style="western">
              <surname>Jones</surname>
              <given-names>L. W.</given-names>
            </string-name> (<year>2021</year>) <article-title>Effects and tolerability of exercise therapy modality on cardiorespiratory fitness in lung cancer: a randomized controlled trial</article-title>, <source>Journal of Cachexia, Sarcopenia and Muscle</source>, <volume>12</volume>, <fpage>1456</fpage>–<lpage>1465</lpage>, <pub-id pub-id-type="doi">10.1002/jcsm.12828</pub-id>
            <pub-id pub-id-type="pmcid">PMC8718021</pub-id>
            <pub-id pub-id-type="pmid">34658160</pub-id>
          </mixed-citation>
        </p>
      </notes>
    </front>
    <body id="jcsm12828-body-0001">
      <sec id="jcsm12828-sec-0005">
        <title>Introduction</title>
        <p>Improvements in screening, surgical procedures, and more effective combination chemotherapeutic regimens have resulted in significant survival gains in post‐surgical lung cancer.<xref rid="jcsm12828-bib-0001" ref-type="bibr">
            <sup>1</sup>
          </xref> Consequently, longer‐term disease and treatment‐related morbidity and mortality are now of major clinical importance in patient‐centred, comprehensive lung cancer management. Poor cardiorespiratory fitness (CRF) is a cardinal feature in post‐treatment lung cancer survivors. Impaired CRF is a consequence of direct as well as indirect (i.e. lifestyle perturbations) adverse effects of surgery and adjuvant therapy on all organ components of the cardiopulmonary system.<xref rid="jcsm12828-bib-0002" ref-type="bibr">
            <sup>2</sup>
          </xref>, <xref rid="jcsm12828-bib-0003" ref-type="bibr">
            <sup>3</sup>
          </xref> Poor CRF is associated with poor survival from both cancer‐related and non‐cancer‐related causes as well as higher symptom burden (e.g. poor quality of life and fatigue).<xref rid="jcsm12828-bib-0004" ref-type="bibr">
            <sup>4</sup>
          </xref>, <xref rid="jcsm12828-bib-0005" ref-type="bibr">
            <sup>5</sup>
          </xref> Thus, strategies to improve CRF in lung cancer survivors are of major clinical importance.<xref rid="jcsm12828-bib-0006" ref-type="bibr">
            <sup>6</sup>
          </xref>
        </p>
        <p>Mechanistically, impaired CRF in lung cancer survivors is likely governed by both central (e.g. reduced convective O₂ transport) and peripheral (e.g. decreased diffusive O<sub>2</sub> transport and oxidative capacity in the skeletal muscle) factors.<xref rid="jcsm12828-bib-0007" ref-type="bibr">
            <sup>7</sup>
          </xref> Aerobic (exercise) training (AT) is arguably the most effective method to improve CRF in healthy humans given favourable adaptations across all O<sub>2</sub> transport components (except lung diffusion capacity<xref rid="jcsm12828-bib-0008" ref-type="bibr">
            <sup>8</sup>
          </xref>). Findings from several studies indicate that AT is a safe and effective intervention for lung cancer patients<xref rid="jcsm12828-bib-0009" ref-type="bibr">
            <sup>9</sup>
          </xref>, <xref rid="jcsm12828-bib-0010" ref-type="bibr">
            <sup>10</sup>
          </xref>, <xref rid="jcsm12828-bib-0011" ref-type="bibr">
            <sup>11</sup>
          </xref>; however, the improvements in CRF were modest (&lt;15%), particularly in the post‐operative setting (~10%), despite good exercise attendance rates (≥70% of planned sessions).<xref rid="jcsm12828-bib-0012" ref-type="bibr">
            <sup>12</sup>
          </xref>, <xref rid="jcsm12828-bib-0013" ref-type="bibr">
            <sup>13</sup>
          </xref> Although less recognized, resistance training (RT) also improves CRF in older adults, possibly through improvements in peripheral limitations (e.g. diffusive O<sub>2</sub> delivery to the mitochondria)<xref rid="jcsm12828-bib-0014" ref-type="bibr">
            <sup>14</sup>
          </xref> and concomitant improvements in muscle quality (e.g. strength). Hence, it appears reasonable to posit that single‐modality AT or RT will confer improvements in CRF. However, a combination training (CT) approach that effectively targets both central and peripheral limitations may confer superior improvements in CRF response among lung cancer survivors.<xref rid="jcsm12828-bib-0015" ref-type="bibr">
            <sup>15</sup>
          </xref> The most effective exercise therapy regimen to improve CRF has not been determined in lung cancer or any respiratory disease condition.</p>
        <p>We conducted a randomized controlled trial (RCT) to evaluate the effects of three different exercise regimens, relative to control, in post‐treatment lung cancer survivors.<xref rid="jcsm12828-bib-0016" ref-type="bibr">
            <sup>16</sup>
          </xref> The primary objective was to evaluate changes in CRF. Secondary objectives were to evaluate changes in upper and lower body maximal strength, body composition, patient‐reported outcomes (PROs), safety, and tolerability.</p>
      </sec>
      <sec sec-type="methods" id="jcsm12828-sec-0006">
        <title>Methods</title>
        <sec id="jcsm12828-sec-0007">
          <title>Trial design and patients</title>
          <p>The full methods are provided in the <xref rid="jcsm12828-supitem-0001" ref-type="supplementary-material">Supporting Information</xref> and are available elsewhere.<xref rid="jcsm12828-bib-0016" ref-type="bibr">
              <sup>16</sup>
            </xref> Using a parallel‐group, factorial RCT design, we evaluated AT, RT, or both (CT), relative to attention control (AC), in lung cancer survivors at Duke University Medical Center (DUMC) and Memorial Sloan‐Kettering Cancer Center (MSKCC). Eligible patients were (i) ≥1 to &lt;10 years after completion of all definitive therapy (i.e. surgery and adjuvant radiation or chemotherapy, as applicable); (ii) age 21–80; (iii) Eastern Cooperative Oncology Group ≤1; (iv) life expectancy ≥4 months; (v) performing less than 150 min of structured moderate‐intensity exercise per week<xref rid="jcsm12828-bib-0017" ref-type="bibr">
              <sup>17</sup>
            </xref>; (vi) able to complete an acceptable cardiopulmonary exercise test (CPET) and one‐repetition maximum muscular strength test; and (vii) confirmed poor CRF—that is, peak oxygen consumption (VO<sub>2</sub>peak) below age–sex‐matched inactive levels.<xref rid="jcsm12828-bib-0018" ref-type="bibr">
              <sup>18</sup>
            </xref>, <xref rid="jcsm12828-bib-0019" ref-type="bibr">
              <sup>19</sup>
            </xref> Exclusion criteria included (i) concurrent malignancy or history of other malignancy treated within the past 3 years, (ii) room air desaturation at rest ≤85%, and (iii) any absolute contraindication to CPET per guidelines.<xref rid="jcsm12828-bib-0020" ref-type="bibr">
              <sup>20</sup>
            </xref>
          </p>
          <p>Patients were randomly assigned in a 1:1:1:1 ratio to receive either one of the three exercise therapy regimens (AT, RT, or CT) or AC. The random allocation sequence was generated and implemented using REDCap with a random permuted block design. Two stratification factors were employed: (i) adjuvant chemotherapy (yes vs. no) and (ii) sex (male vs. female). Group allocation was concealed until treatment intervention was assigned. The trial primary statisticians (J. H. and S. M. T.) generated the random sequence; dedicated study coordinators enrolled patients, and the clinical research team at each centre assigned participants to treatment group. Exercise physiologists implementing the study interventions were not randomly allocated to study treatment arms. Neither patients nor exercise physiologists were blinded to group allocation. Participants and study investigators were blinded to results at pre‐randomization and post‐intervention. Study investigators were blinded to treatment allocation. All study procedures were reviewed and approved by the DUMC and MSKCC institutional review boards. All patients provided written informed consent.</p>
        </sec>
        <sec id="jcsm12828-sec-0008">
          <title>Interventions</title>
          <p>Exercise therapy in all three regimens consisted of 48 individualized (one on one), supervised sessions, three times weekly for 16 consecutive weeks. Dedicated study personnel with at least bachelor's degrees in exercise science implemented the interventions and individually monitored all sessions. No informational material was provided to study participants. All intervention sessions were conducted in a dedicated exercise training facility on hospital campus at both study sites.</p>
          <p>Aerobic training consisted of stationary cycle ergometry (Technogym Excite; Precor UBK 835) dosed at one of five different intensities (i.e. 55%, 65%, 75%, 80%, and &gt;95%) individualized to each patient on the basis of workload (i.e. Watts) corresponding to a specific per cent of ventilatory thresholds measured during the pre‐randomization or midpoint (Week 8) CPET. Ventilatory threshold was identified from the CPET by a trained exercise physiologist defined by the following criteria: (i) drop in fraction of expired carbon dioxide oxygen content after a peak or plateau, (ii) non‐linear increase in minute ventilation, and (iii) respiratory exchange ratio between 0.98 and 1.02. All sessions were 20–60 min per session depending on intensity; interval sessions consisted of 60–120 s at VO<sub>2</sub>peak followed by 120–180 s of active recovery for 4–10 intervals per session. Dose was sequenced and continually progressed consistent with non‐linear (periodized) training.<xref rid="jcsm12828-bib-0021" ref-type="bibr">
              <sup>21</sup>
            </xref>
          </p>
          <p>Resistance training was progressively increased during an initial 2 week ramp period to perform three sets of 6–18 repetitions of 14 resistance exercises (i.e. chest press, seated row, lateral pull down, pec deck, bicep curl, triceps extension, push‐up, leg press, leg curl, leg extension, hip abduction, hip adduction, step up, and sit‐to‐stand) alternating between lower and upper extremity muscle groups for 30–60 min per session. Intensity was individualized to each patient on the basis of maximal strength corresponding to a specific percent of a one‐repetition maximum (1‐RM) measured during the pre‐randomization or midpoint (Week 8). Specifically, in Weeks 1 and 2, all three sessions per week were performed at an intensity of 50–60% of 1‐RM for 2–3 sets of 10–15 repetitions for both upper and lower body exercises. In Weeks 3–8, one session per week was 70–80% of 1‐RM for three sets of 8–10 repetitions for upper body exercise; one session per week was 60–65% of 1‐RM for three sets of 15–18 repetitions for lower body exercises; and the remaining session was a combination of the two previous days. In Weeks 9–16, one session per week was 75–85% of 1‐RM for three sets of 6–10 repetitions for upper body exercises; one session per week was 70–75% of 1‐RM for two to three sets of 10–12 repetitions for lower body exercises; and the remaining session was a combination of the two previous days.</p>
          <p>The CT group consisted of three AT plus RT sessions per week for Weeks 1–8, and two AT plus RT and one interval AT sessions per week for Weeks 9–16. CT followed AT and RT dosing schedules for a total of 30–90 min per session. Within each session, AT was performed first followed by RT. Sequencing of AT and RT, both within each CT session and across the entire intervention period, was designed to exploit the complementary effects of each individual modality to augment CRF. Finally, AC consisted of 12–20 different stretching positions for 20–45 s per stretch following a standardized progressive individualized prescription for a total of 20–45 min per session.<xref rid="jcsm12828-bib-0022" ref-type="bibr">
              <sup>22</sup>
            </xref> Dose modification was permitted and performed using standardized criteria (<italic toggle="yes">Table</italic>
            <xref rid="jcsm12828-supitem-0001" ref-type="supplementary-material">S1</xref>) in all groups. Relative dose intensity (RDI) was defined as the ratio of total ‘completed’ to total ‘planned’ cumulative dose, as described previously.<xref rid="jcsm12828-bib-0022" ref-type="bibr">
              <sup>22</sup>
            </xref>, <xref rid="jcsm12828-bib-0023" ref-type="bibr">
              <sup>23</sup>
            </xref>
          </p>
        </sec>
        <sec id="jcsm12828-sec-0009">
          <title>Endpoints</title>
          <p>The primary endpoint was change in CRF (VO<sub>2</sub>peak, mL O<sub>2</sub>·kg<sup>−1</sup>·min<sup>−1</sup>) evaluated by a symptom‐limited CPET on an electronic cycle ergometer (Corival, Lode, NI) with breath‐by‐breath expired gas analysis (ParvoMedics, TrueOne 2400, Salt Lake City, UT, USA) with 12‐lead electrocardiogram monitoring (Mac<sup>®</sup> 5000, GE Healthcare, Chicago, IL, USA).<xref rid="jcsm12828-bib-0024" ref-type="bibr">
              <sup>24</sup>
            </xref> All patients performed two pre‐randomization CPETs (≤30 days of each other) under similar laboratory conditions (<italic toggle="yes">Figure</italic>
            <xref rid="jcsm12828-supitem-0001" ref-type="supplementary-material">S1</xref>). If both were acceptable, the highest recorded measure was selected (the second CPET was selected in &gt;80% of patients).</p>
          <p>Secondary endpoints were other CPET variables, maximal muscular strength, PROs, and tolerability and safety.<xref rid="jcsm12828-bib-0023" ref-type="bibr">
              <sup>23</sup>
            </xref> Maximal muscular strength was assessed by 1‐RM of chest press and seated row for upper body extremity and leg press for lower body extremity and body weight and composition [weight (kg); percentage of lean and fat mass assessed via a dual‐energy X‐ray absorptiometry (Lunar DPX, General Electric) or air displacement plethysmography (Life Measurement, Inc., Concord, CA, USA)]. PROs were evaluated using quality of life [Functional Assessment of Cancer Therapy—Lung<xref rid="jcsm12828-bib-0025" ref-type="bibr">
              <sup>25</sup>
            </xref> that contains the subscales for physical well‐being, social well‐being, emotional well‐being, and functional well‐being that comprise the Functional Assessment of Cancer Therapy—General,<xref rid="jcsm12828-bib-0026" ref-type="bibr">
              <sup>26</sup>
            </xref> plus a lung cancer subscale, Functional Assessment of Chronic Illness Therapy—Fatigue Scale,<xref rid="jcsm12828-bib-0027" ref-type="bibr">
              <sup>27</sup>
            </xref> pain (Brief Pain Inventory),<xref rid="jcsm12828-bib-0028" ref-type="bibr">
              <sup>28</sup>
            </xref> and sleep quality (Pittsburgh Sleep Quality Index)<xref rid="jcsm12828-bib-0029" ref-type="bibr">
              <sup>29</sup>
            </xref>] instruments. All endpoints were evaluated at pre‐randomization and repeated ≤14 days after the final intervention session (Week 17).</p>
          <p>Tolerability was assessed by RDI (defined as the ratio of total ‘completed’ to total ‘planned’ cumulative dose)<xref rid="jcsm12828-bib-0022" ref-type="bibr">
              <sup>22</sup>
            </xref> and rate of lost to follow‐up (LTF; lack of completion of post‐intervention assessments), attendance (ratio of total attended to planned treatments), permanent discontinuation (treatment discontinuation prior to Week 16), treatment interruption (missing ≥3 consecutive planned sessions), dose modification [≥10% of sessions requiring modification (reduction/escalation) of intensity and/or duration], pretreatment dose modification (reduction of pretreatment session intensity), and early session termination (termination of session prior to planned duration). Safety was evaluated by the type and prevalence of serious (i.e. life‐threatening, hospitalization, significant incapacity, and important medical events) and non‐serious (e.g. knee and back pain) adverse events during CPET and exercise sessions by the dedicated exercise physiologists.</p>
        </sec>
        <sec id="jcsm12828-sec-0010">
          <title>Statistical analysis</title>
          <p>This RCT was designed to accrue 160 patients (<italic toggle="yes">n</italic> = 40 per group).<xref rid="jcsm12828-bib-0016" ref-type="bibr">
              <sup>16</sup>
            </xref> Power calculations assumed a standard deviation of 3.0 mL O<sub>2</sub>·kg<sup>−1</sup>·min<sup>−1</sup> based on prior work.<xref rid="jcsm12828-bib-0012" ref-type="bibr">
              <sup>12</sup>
            </xref> With a total accrual of 160 patients, 80% power was obtained under the assumption that mean change in VO<sub>2</sub>peak for the AT, RT, CT, and AC groups was 0.60, 0.60, 2.10, and 0.0 mL O<sub>2</sub>·kg<sup>−1</sup>·min<sup>−1</sup>, respectively.<xref rid="jcsm12828-bib-0016" ref-type="bibr">
              <sup>16</sup>
            </xref> The primary analysis used an analysis of covariance to estimate the association of study group with change from baseline to Week 17 for the primary and secondary endpoints. Comparisons between exercise regimens were for exploratory purposes only. Analyses were adjusted for baseline values of the endpoint and other variables displaying imbalance across group assignment. Hence, all analyses were adjusted for age, body mass index, and co‐morbidities [i.e. coronary artery disease, chronic obstructive pulmonary disease (COPD), and hypertension].</p>
          <p>All analyses were conducted under the intention‐to‐treat principle. Missing values for the primary endpoint were imputed with both multiple imputation using a Monte Carlo Markov single‐chain method assuming a multivariate normal distribution and initial mean and covariance estimates derived using the expectation–maximization algorithm and last observation carried forward (LOCF). Results of both approaches were similar; thus, only data from LOCF analyses are reported. LOCF was also used for missing values in secondary endpoints. Changes between baseline and Week 17 were estimated for each patient individually; the mean change within each group was used to estimate group differences. The proportion of patients in each exercise group with a VO<sub>2</sub>peak improvement greater than the technical error (TE) was calculated as previously described<xref rid="jcsm12828-bib-0030" ref-type="bibr">
              <sup>30</sup>
            </xref>; the TE was ≥1.12 mL O<sub>2</sub>·kg<sup>−1</sup>·min<sup>−1</sup>. Fisher's exact test was used to test for differences between groups. Analysis of covariance was used to estimate the association of study group and RDI with adjustment for the covariates defined previously; other tolerability measures were compared across arms with the Kruskal–Wallis test for continuous variables and Fisher's exact test for categorical variables. All analyses were conducted using SAS Version 9.4 (SAS Institute, Cary, NC, USA).</p>
        </sec>
      </sec>
      <sec sec-type="results" id="jcsm12828-sec-0011">
        <title>Results</title>
        <p>A total of 90 patients (56% of planned accrual goal) were randomly allocated to AT (<italic toggle="yes">n</italic> = 24), RT (<italic toggle="yes">n</italic> = 23), CT (<italic toggle="yes">n</italic> = 20), or AC (<italic toggle="yes">n</italic> = 23) (<italic toggle="yes">Figure</italic>
          <xref rid="jcsm12828-fig-0001" ref-type="fig">1</xref>). Recruitment was terminated early because of slow accrual. The trial was conducted at DUMC between February 2010 and May 2013, continuing at MSKCC from April 2017 to March 2018 (for a total accrual period of 4.3 years), with final post‐intervention testing conducted in July 2018. Baseline characteristics were balanced between arms (<italic toggle="yes">Table</italic>
          <xref rid="jcsm12828-tbl-0001" ref-type="table">1</xref>). For the overall cohort, mean pre‐randomization VO<sub>2</sub>peak was 15.8 ± 4.5 mL O<sub>2</sub>·kg<sup>−1</sup>·min<sup>−1</sup>, the equivalent of 42% and 50% below age‐matched healthy sedentary women and men, respectively.<xref rid="jcsm12828-bib-0018" ref-type="bibr">
            <sup>18</sup>
          </xref>, <xref rid="jcsm12828-bib-0019" ref-type="bibr">
            <sup>19</sup>
          </xref> Non‐protocol exercise increased in all groups with no differences between groups (<italic toggle="yes">P</italic> = 0.12).</p>
        <fig position="float" fig-type="Figure" id="jcsm12828-fig-0001" orientation="portrait">
          <label>Figure 1</label>
          <caption>
            <p>F CONSORT flow for non‐pharmacological trials.</p>
          </caption>
          <graphic position="anchor" id="jats-graphic-1" orientation="portrait" ns0:href="JCSM-12-1456-g001.jpg" />
        </fig>
        <table-wrap position="float" id="jcsm12828-tbl-0001" content-type="Table" orientation="portrait">
          <label>Table 1</label>
          <caption>
            <p>Characteristics of the participants at baseline</p>
          </caption>
          <table frame="hsides" rules="groups">
            <col align="left" span="1" />
            <col align="left" span="1" />
            <col align="left" span="1" />
            <col align="left" span="1" />
            <col align="left" span="1" />
            <col align="left" span="1" />
            <thead valign="bottom">
              <tr style="border-bottom:solid 1px #000000">
                <th align="left" valign="bottom" rowspan="1" colspan="1">Characteristic</th>
                <th align="center" valign="bottom" rowspan="1" colspan="1">All patients (<italic toggle="no">n</italic> = 90)</th>
                <th align="center" valign="bottom" rowspan="1" colspan="1">Aerobic training (<italic toggle="no">n</italic> = 24)</th>
                <th align="center" valign="bottom" rowspan="1" colspan="1">Resistance training (<italic toggle="no">n</italic> = 23)</th>
                <th align="center" valign="bottom" rowspan="1" colspan="1">Combination training (<italic toggle="no">n</italic> = 20)</th>
                <th align="center" valign="bottom" rowspan="1" colspan="1">Attention control (<italic toggle="no">n</italic> = 23)</th>
              </tr>
            </thead>
            <tbody valign="top">
              <tr>
                <td align="left" valign="top" rowspan="1" colspan="1">Age (years), mean ± SD</td>
                <td align="left" valign="top" rowspan="1" colspan="1">65 ± 9</td>
                <td align="left" valign="top" rowspan="1" colspan="1">64 ± 9</td>
                <td align="left" valign="top" rowspan="1" colspan="1">64 ± 9</td>
                <td align="left" valign="top" rowspan="1" colspan="1">63 ± 11</td>
                <td align="left" valign="top" rowspan="1" colspan="1">67 ± 8</td>
              </tr>
              <tr>
                <td align="left" valign="top" rowspan="1" colspan="1">Male, no. (%)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">31 (34)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">9 (37)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">8 (35)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">7 (35)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">7 (30)</td>
              </tr>
              <tr>
                <td align="left" valign="top" rowspan="1" colspan="1">BMI (kg·m<sup>−2</sup>), mean ± SD</td>
                <td align="left" valign="top" rowspan="1" colspan="1">28 ± 6</td>
                <td align="left" valign="top" rowspan="1" colspan="1">26 ± 6</td>
                <td align="left" valign="top" rowspan="1" colspan="1">27 ± 6</td>
                <td align="left" valign="top" rowspan="1" colspan="1">27 ± 4</td>
                <td align="left" valign="top" rowspan="1" colspan="1">30 ± 6</td>
              </tr>
              <tr>
                <td colspan="6" align="left" valign="top" rowspan="1">Site, no. (%)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">DUMC</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">78 (87)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">20 (83)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">20 (87)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">19 (95)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">19 (83)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">MSKCC</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">12 (13)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">4 (17)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (13)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">1 (5)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">4 (17)</td>
              </tr>
              <tr>
                <td align="left" valign="top" rowspan="1" colspan="1">Exercise (min·week<sup>−1</sup>)<xref rid="jcsm12828-note-0004" ref-type="table-fn">
                    <sup>a</sup>
                  </xref>, mean ± SD</td>
                <td align="left" valign="top" rowspan="1" colspan="1">80 ± 101</td>
                <td align="left" valign="top" rowspan="1" colspan="1">122 ± 108</td>
                <td align="left" valign="top" rowspan="1" colspan="1">61 ± 128</td>
                <td align="left" valign="top" rowspan="1" colspan="1">71 ± 69</td>
                <td align="left" valign="top" rowspan="1" colspan="1">58 ± 80</td>
              </tr>
              <tr>
                <td colspan="6" align="left" valign="top" rowspan="1">Smoking, no. (%)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Never</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">11 (12)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">6 (25)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (9)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">1 (5)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (9)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Former</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">74 (82)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">17 (71)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">19 (83)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">17 (85)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">21 (91)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Current</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">5 (6)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">1 (4)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (9)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (10)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0)</td>
              </tr>
              <tr>
                <td colspan="6" align="left" valign="top" rowspan="1">Disease stage, no. (%)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">I</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">1 (1)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">1 (4)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">IA</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">35 (39)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">10 (42)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">8 (35)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">9 (45)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">8 (35)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">IB</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">22 (24)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">4 (17)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">6 (26)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">5 (25)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">7 (30)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">IIA</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">10 (11)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (8)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">4 (17)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (10)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (9)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">IIB</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">8 (9)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (12)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">1 (4)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">1 (5)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (13)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">IIIA</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">11 (12)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (12)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (13)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (10)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (13)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">IIIB</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (2)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">1 (4)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">1 (5)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Limited stage</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">1 (1)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">1 (4)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0)</td>
              </tr>
              <tr>
                <td colspan="6" align="left" valign="top" rowspan="1">Adjuvant therapy, no. (%)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Received chemotherapy</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">38 (42)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">11 (46)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">10 (43)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">8 (40)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">9 (39)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Received radiotherapy</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">15 (16)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">5 (21)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">4 (17)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (10)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">4 (17)</td>
              </tr>
              <tr>
                <td align="left" valign="top" rowspan="1" colspan="1">Resection degree, no. (%)</td>
                <td align="left" valign="top" rowspan="1" colspan="1" />
                <td align="left" valign="top" rowspan="1" colspan="1" />
                <td align="left" valign="top" rowspan="1" colspan="1" />
                <td align="left" valign="top" rowspan="1" colspan="1" />
                <td align="left" valign="top" rowspan="1" colspan="1" />
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Lobectomy</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">70 (78)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">17 (71)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">20 (87)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">16 (80)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">17 (74)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Pneumonectomy</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">5 (6)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">1 (4)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (10)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (9)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Bilobectomy</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">1 (1)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">1 (4)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Wedge resection</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">10 (11)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">4 (17)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (13)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">1 (5)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (9)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Segment resection</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (3)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (10)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">1 (4)</td>
              </tr>
              <tr>
                <td colspan="6" align="left" valign="top" rowspan="1">Current medications, no. (%)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Beta‐blockers</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">14 (16)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (13)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">5 (22)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (10)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">4 (17)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">ACE inhibitors</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">11 (12)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (8)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (9)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">4 (20)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (13)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Angiotensin receptor blockers</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">7 (8)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">1 (4)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (9)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">1 (5)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (13)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Diuretic</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">11 (12)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (13)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (9)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (15)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (13)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Aspirin/anti‐platelet</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">25 (28)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">6 (25)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">8 (35)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">6 (30)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">5 (22)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Statins</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">30 (33)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">12 (50)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">5 (22)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">8 (40)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">5 (22)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Calcium channel blocker</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">16 (18)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (8)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">6 (26)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (15)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">5 (22)</td>
              </tr>
              <tr>
                <td colspan="6" align="left" valign="top" rowspan="1">Pre‐existing (controlled) co‐morbidities, no. (%)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">CAD</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">15 (17)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (8)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">5 (22)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">4 (20)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">4 (17)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">COPD</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">20 (22)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (8)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">7 (30)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">7 (35)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">4 (17)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Arthritis</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">21 (23)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">5 (21)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">4 (17)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">5 (25)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">7 (30)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Type 2 diabetes</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">9 (10)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">1 (4)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">4 (17)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (10)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (9)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Hyperlipidaemia</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">39 (43)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">12 (50)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">11 (48)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">7 (35)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">9 (39)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Hypertension</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">45 (50)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">8 (33)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">13 (56)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">10 (50)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">14 (61)</td>
              </tr>
              <tr>
                <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Any</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">66 (73)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">17 (71)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">18 (78)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">15 (75)</td>
                <td align="char" char="(" valign="top" rowspan="1" colspan="1">16 (70)</td>
              </tr>
              <tr>
                <td align="left" valign="top" rowspan="1" colspan="1">Pre‐randomization VO<sub>2</sub>peak (mL O<sub>2</sub>·kg<sup>−1</sup>·min<sup>−1</sup>), mean ± SD</td>
                <td align="left" valign="top" rowspan="1" colspan="1">15.8 ± 4.5</td>
                <td align="left" valign="top" rowspan="1" colspan="1">17.9 ± 5.5</td>
                <td align="left" valign="top" rowspan="1" colspan="1">15.2 ± 3.2</td>
                <td align="left" valign="top" rowspan="1" colspan="1">15.2 ± 4.5</td>
                <td align="left" valign="top" rowspan="1" colspan="1">14.5 ± 4.1</td>
              </tr>
              <tr>
                <td style="padding-left:10%" colspan="6" align="left" valign="top" rowspan="1">% below age‐matched, mean ± SD</td>
              </tr>
              <tr>
                <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Men</td>
                <td align="left" valign="top" rowspan="1" colspan="1">50 ± 14</td>
                <td align="left" valign="top" rowspan="1" colspan="1">42 ± 17</td>
                <td align="left" valign="top" rowspan="1" colspan="1">55 ± 10</td>
                <td align="left" valign="top" rowspan="1" colspan="1">54 ± 9</td>
                <td align="left" valign="top" rowspan="1" colspan="1">51 ± 17</td>
              </tr>
              <tr>
                <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Women</td>
                <td align="left" valign="top" rowspan="1" colspan="1">42 ± 15</td>
                <td align="left" valign="top" rowspan="1" colspan="1">35 ± 18</td>
                <td align="left" valign="top" rowspan="1" colspan="1">44 ± 14</td>
                <td align="left" valign="top" rowspan="1" colspan="1">45 ± 14</td>
                <td align="left" valign="top" rowspan="1" colspan="1">46 ± 14</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot id="jcsm12828-ntgp-0002">
            <fn id="jcsm12828-note-0002">
              <p>ACE, angiotensin‐converting enzyme; BMI, body mass index; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; DUMC, Duke University Medical Center; MSKCC, Memorial Sloan‐Kettering Cancer Center; SD, standard deviation.</p>
            </fn>
            <fn id="jcsm12828-note-0003">
              <p>All comparisons <italic toggle="yes">P</italic> &gt; 0.05. Chemotherapy, radiation, and endocrine therapy rates include only those patients receiving each treatment.</p>
            </fn>
            <fn id="jcsm12828-note-0004">
              <label>
                <sup>a</sup>
              </label>
              <p>Exercise defined as the total minutes of self‐reported moderate/vigorous exercise per week.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <sec id="jcsm12828-sec-0012">
          <title>Efficacy</title>
          <p>For the primary endpoint, VO<sub>2</sub>peak increased by 1.1 mL O<sub>2</sub>·kg<sup>−1</sup>·min<sup>−1</sup> in the AT group [95% confidence interval (CI): 0.0, 2.2, <italic toggle="yes">P</italic> = 0.04] and by 1.4 mL O<sub>2</sub>·kg<sup>−1</sup>·min<sup>−1</sup> in the CT group (95% CI: 0.2, 2.5, <italic toggle="yes">P</italic> = 0.02) compared with AC (<italic toggle="yes">Table</italic>
            <xref rid="jcsm12828-tbl-0002" ref-type="table">2</xref>). There was no difference in VO<sub>2</sub>peak change between RT and AC (−0.1 mL O<sub>2</sub>·kg<sup>−1</sup>·min<sup>−1</sup>, 95% CI: −1.2, 1.0, <italic toggle="yes">P</italic> = 0.88). The range of VO<sub>2</sub>peak change in the AT group was −3.3 to 6.3 mL O<sub>2</sub>·kg<sup>−1</sup>·min<sup>−1</sup>, −3.2 to 4.9 mL O<sub>2</sub>·kg<sup>−1</sup>·min<sup>−1</sup> in RT, and −2.3 to 5.7 mL O<sub>2</sub>·kg<sup>−1</sup>·min<sup>−1</sup> in CT, compared with −3.2 to 4.1 mL O<sub>2</sub>·kg<sup>−1</sup>·min<sup>−1</sup> in AC (<italic toggle="yes">Figure</italic>
            <xref rid="jcsm12828-fig-0002" ref-type="fig">2</xref>). The proportion of patients in the AT, RT, and CT groups with a VO<sub>2</sub>peak response greater than the TE (i.e. 1.12 mL O<sub>2</sub>·kg<sup>−1</sup>·min<sup>−1</sup>) was 50%, 13%, and 50%, respectively, compared with 13% in the AC group (<italic toggle="yes">P</italic> = 0.01).</p>
          <table-wrap position="float" id="jcsm12828-tbl-0002" content-type="Table" orientation="portrait">
            <label>Table 2</label>
            <caption>
              <p>Effects on primary and secondary endpoints (intention‐to‐treat analysis)</p>
            </caption>
            <table frame="hsides" rules="groups">
              <col align="left" span="1" />
              <col align="char" char="(" span="1" />
              <col align="char" char="." span="1" />
              <col align="char" char="(" span="1" />
              <col align="char" char="." span="1" />
              <col align="char" char="(" span="1" />
              <col align="char" char="." span="1" />
              <col align="char" char="." span="1" />
              <thead valign="bottom">
                <tr style="border-bottom:solid 1px #000000">
                  <th align="left" style="border-bottom:solid 1px #000000" rowspan="2" valign="bottom" colspan="1">Variable</th>
                  <th align="center" style="border-bottom:solid 1px #000000" colspan="6" valign="bottom" rowspan="1">Parameter estimate (95% confidence interval)</th>
                  <th align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1" />
                </tr>
                <tr style="border-bottom:solid 1px #000000">
                  <th align="center" valign="bottom" rowspan="1" colspan="1">AT vs. AC</th>
                  <th align="center" valign="bottom" rowspan="1" colspan="1">
                    <italic toggle="no">P</italic>
                    <xref rid="jcsm12828-note-0007" ref-type="table-fn">
                      <sup>a</sup>
                    </xref>
                  </th>
                  <th align="center" valign="bottom" rowspan="1" colspan="1">RT vs. AC</th>
                  <th align="center" valign="bottom" rowspan="1" colspan="1">
                    <italic toggle="no">P</italic>
                    <xref rid="jcsm12828-note-0007" ref-type="table-fn">
                      <sup>a</sup>
                    </xref>
                  </th>
                  <th align="center" valign="bottom" rowspan="1" colspan="1">CT vs. AC</th>
                  <th align="center" valign="bottom" rowspan="1" colspan="1">
                    <italic toggle="no">P</italic>
                    <xref rid="jcsm12828-note-0007" ref-type="table-fn">
                      <sup>a</sup>
                    </xref>
                  </th>
                  <th align="center" valign="bottom" rowspan="1" colspan="1">Overall <italic toggle="no">P</italic>
                    <xref rid="jcsm12828-note-0007" ref-type="table-fn">
                      <sup>a</sup>
                    </xref>
                  </th>
                </tr>
              </thead>
              <tbody valign="top">
                <tr>
                  <td colspan="8" align="left" valign="top" rowspan="1">Primary endpoint</td>
                </tr>
                <tr>
                  <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">VO<sub>2</sub>peak (mL O<sub>2</sub>·kg<sup>−1</sup>·min<sup>−1</sup>)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">1.1 (0, 2.2)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.04</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">−0.1 (−1.2, 1)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.88</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">1.4 (0.2, 2.5)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.02</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.02</td>
                </tr>
                <tr>
                  <td colspan="8" align="left" valign="top" rowspan="1">Secondary endpoints</td>
                </tr>
                <tr>
                  <td style="padding-left:10%" colspan="8" align="left" valign="top" rowspan="1">Resting cardiopulmonary function</td>
                </tr>
                <tr>
                  <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Heart rate (b.p.m.)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">2.1 (−2.8, 7.1)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.39</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">2.7 (−2.4, 7.7)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.30</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">−0.8 (−5.9, 4.3)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.75</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.48</td>
                </tr>
                <tr>
                  <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Systolic blood pressure (mmHg)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">1.7 (−5.1, 8.6)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.62</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">2.6 (−4.3, 9.4)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.46</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">−1.6 (−8.7, 5.5)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.65</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.64</td>
                </tr>
                <tr>
                  <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Diastolic blood pressure (mmHg)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.4 (−4.3, 5.2)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.86</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.1 (−4.6, 4.8)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.96</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">−0.6 (−5.5, 4.3)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.80</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.98</td>
                </tr>
                <tr>
                  <td style="padding-left:10%" colspan="8" align="left" valign="top" rowspan="1">Peak cardiopulmonary function</td>
                </tr>
                <tr>
                  <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">VO<sub>2</sub>peak (L<sup>.</sup>min<sup>−1</sup>)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.1 (0, 0.1)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.09</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0 (−0.1, 0.1)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.82</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.1 (0, 0.2)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.005</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.02</td>
                </tr>
                <tr>
                  <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Respiratory exchange ratio</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0 (0, 0.1)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.19</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0 (−0.1, 0)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.46</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0 (−0.1, 0)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.30</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.10</td>
                </tr>
                <tr>
                  <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Ventilation (L<sup>.</sup>min<sup>−1</sup>)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">4.0 (0.1, 7.9)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.04</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">−0.7 (−4.6, 3.2)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.73</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">4.2 (0.1, 8.2)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.04</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.02</td>
                </tr>
                <tr>
                  <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Heart rate (b.p.m.)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">7.2 (1.7, 12.8)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.01</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">1.4 (−4.2, 6.9)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.63</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">3.3 (−2.5, 9)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.26</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.06</td>
                </tr>
                <tr>
                  <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Systolic blood pressure (mmHg)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">4.2 (−5.7, 14.2)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.40</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">3.8 (−6.3, 13.9)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.46</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">4.3 (−6.5, 15)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.43</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.82</td>
                </tr>
                <tr>
                  <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Diastolic blood pressure (mmHg)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">1.7 (−3.6, 7)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.53</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">2.2 (−3, 7.5)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.40</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">3.0 (−2.7, 8.7)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.29</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.75</td>
                </tr>
                <tr>
                  <td style="padding-left:10%" colspan="8" align="left" valign="top" rowspan="1">Strength</td>
                </tr>
                <tr>
                  <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">1‐RM leg press (lb)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">5.3 (−15.1, 25.7)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.61</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">24.2 (4.1, 44.4)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.02</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">16.5 (−4.4, 37.3)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.12</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.08</td>
                </tr>
                <tr>
                  <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">1‐RM chest press (lb)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">−0.6 (−13.4, 12.3)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.93</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">20.4 (8.2, 32.6)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">6.0 (−6.6, 18.7)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.34</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.003</td>
                </tr>
                <tr>
                  <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">1‐RM seated row (lb)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">−7.6 (−15.6, 0.5)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.06</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">7.7 (0.1, 15.3)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.04</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">3.7 (−4.2, 11.5)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.36</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.001</td>
                </tr>
                <tr>
                  <td style="padding-left:10%" colspan="8" align="left" valign="top" rowspan="1">Body weight and composition</td>
                </tr>
                <tr>
                  <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Weight (kg)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">1.1 (0, 2.3)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.06</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.6 (−0.6, 1.7)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.33</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.2 (−0.9, 1.4)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.71</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.25</td>
                </tr>
                <tr>
                  <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Lean body mass (%)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">−1.0 (−2.8, 0.9)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.29</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">1.6 (−0.2, 3.4)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.08</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">1.1 (−0.8, 3)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.25</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.03</td>
                </tr>
                <tr>
                  <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Fat mass (%)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">1.0 (−0.9, 2.8)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.30</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">−1.6 (−3.4, 0.2)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.08</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">−1.1 (−3, 0.8)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.24</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.03</td>
                </tr>
                <tr>
                  <td style="padding-left:10%" colspan="8" align="left" valign="top" rowspan="1">PROs</td>
                </tr>
                <tr>
                  <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">FACT‐L (0–136)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">2.5 (−2.9, 7.9)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.36</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">−2.0 (−7.1, 3.2)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.46</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">−0.4 (−5.9, 5.2)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.90</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.42</td>
                </tr>
                <tr>
                  <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">FACT‐G total (0–108)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">1.7 (−4.3, 7.8)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.57</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">−0.8 (−6.6, 5.1)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.80</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">−1.1 (−7.4, 5.1)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.72</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.79</td>
                </tr>
                <tr>
                  <td style="padding-left:20%" align="left" valign="top" rowspan="1" colspan="1">Physical well‐being (0–28)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0 (−1.4, 1.4)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.98</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.1 (−1.3, 1.5)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.92</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">−1.2 (−2.6, 0.3)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.11</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.27</td>
                </tr>
                <tr>
                  <td style="padding-left:20%" align="left" valign="top" rowspan="1" colspan="1">Social well‐being (0–28)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">1.4 (−0.9, 3.7)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.22</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">−0.7 (−3, 1.5)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.52</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.8 (−1.6, 3.2)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.50</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.27</td>
                </tr>
                <tr>
                  <td style="padding-left:20%" align="left" valign="top" rowspan="1" colspan="1">Emotional well‐being (0–24)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">−0.7 (−2.7, 1.3)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.50</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">−0.8 (−2.7, 1.2)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.45</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">−0.3 (−2.4, 1.7)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.75</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.87</td>
                </tr>
                <tr>
                  <td style="padding-left:20%" align="left" valign="top" rowspan="1" colspan="1">Functional well‐being (0–28)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">2.0 (−0.4, 4.5)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.10</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">−1.1 (−3.4, 1.3)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.37</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">1.0 (−1.4, 3.5)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.41</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.06</td>
                </tr>
                <tr>
                  <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">FACIT‐Fatigue (0–52)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">−1.7 (−3.8, 0.4)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.11</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.1 (−2, 2.2)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.93</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">−0.5 (−2.7, 1.7)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.64</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.32</td>
                </tr>
                <tr>
                  <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Pain (0–10)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">−0.3 (−0.8, 0.3)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.37</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.2 (−0.4, 0.7)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.52</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">−0.3 (−0.8, 0.3)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.39</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.34</td>
                </tr>
                <tr>
                  <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Sleep (0–28)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">−1.1 (−2.6, 0.4)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.16</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.3 (−1.2, 1.9)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.66</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">−0.8 (−2.4, 0.8)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.33</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.22</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot id="jcsm12828-ntgp-0003">
              <fn id="jcsm12828-note-0005">
                <p>AC, attention control; ANCOVA, analysis of covariance; AT, aerobic training; CT, combination training; FACIT, Functional Assessment of Chronic Illness Therapy; FACT‐G, Functional Assessment of Cancer Therapy—General; FACT‐L, Functional Assessment of Cancer Therapy—Lung; PROs, patient‐reported outcomes; RM, repetition maximum; RT, resistance training.</p>
              </fn>
              <fn id="jcsm12828-note-0006">
                <p>Data presented as parameter estimate (95% confidence interval) as estimated from ANCOVA model with outcome of change adjusted for baseline value and age, body mass index, and co‐morbidities (coronary artery disease, chronic obstructive pulmonary disease, and hypertension).</p>
              </fn>
              <fn id="jcsm12828-note-0007">
                <label>
                  <sup>a</sup>
                </label>
                <p>
                  <italic toggle="yes">P</italic>‐value from ANCOVA model with outcome of change adjusted for baseline factors.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <fig position="float" fig-type="Figure" id="jcsm12828-fig-0002" orientation="portrait">
            <label>Figure 2</label>
            <caption>
              <p>Waterfall plots for change in cardiorespiratory fitness. The technical error for VO<sub>2</sub>peak (Δ1.12 mL O<sub>2</sub>·kg<sup>−1</sup>·min<sup>−1</sup>) is illustrated by the shaded area. A change in cardiorespiratory fitness greater than technical error is classified as a meaningful response. AC, attention control; AT, aerobic training; CT, combination training; RT, resistance training.</p>
            </caption>
            <graphic position="anchor" id="jats-graphic-3" orientation="portrait" ns0:href="JCSM-12-1456-g002.jpg" />
          </fig>
          <p>For secondary endpoints, in comparison with AC, AT was associated with significant improvements in several other cardiopulmonary endpoints including ventilation and peak heart rate (<italic toggle="yes">P</italic>s &lt; 0.05) (<italic toggle="yes">Table</italic>
            <xref rid="jcsm12828-tbl-0002" ref-type="table">2</xref>). Single‐modality RT led to significant improvements in upper and lower extremity maximal strength compared with AC (<italic toggle="yes">P</italic>s &lt; 0.05), while increases in lean mass and reductions in fat mass compared with AC approached significance (<italic toggle="yes">P</italic>s = 0.08) (<italic toggle="yes">Table</italic>
            <xref rid="jcsm12828-tbl-0002" ref-type="table">2</xref>). No between‐group changes were observed for any PROs (<italic toggle="yes">Table</italic>
            <xref rid="jcsm12828-tbl-0002" ref-type="table">2</xref>). Exploratory comparisons between exercise regimens revealed both AT and CT were superior to RT for improvements in several peak cardiopulmonary endpoints, whereas RT‐containing regimens were superior to AT for improvements in maximal muscle, strength, and body composition (<italic toggle="yes">Table</italic>
            <xref rid="jcsm12828-supitem-0001" ref-type="supplementary-material">S2</xref>).</p>
        </sec>
        <sec id="jcsm12828-sec-0013">
          <title>Tolerability and safety</title>
          <p>Relative dose intensity of exercise was significantly lower in RT (−24%; 95% CI: −40, −5, <italic toggle="yes">P</italic> = 0.003) and CT (−30%, 95% CI: −46, −14, <italic toggle="yes">P</italic> &lt; 0.001) groups compared with AT. LTF was 4%, 13%, and 10% in AT, RT, and CT, respectively, compared with 13% in AC (<italic toggle="yes">P</italic> = 0.73), whereas mean attendance was ≥75% in all groups (<italic toggle="yes">P</italic> = 0.35) (<italic toggle="yes">Table</italic>
            <xref rid="jcsm12828-tbl-0003" ref-type="table">3</xref>). Median attendance was 90% (range: 4–100%). Rates of permanent discontinuation were 4%, 22%, and 25% in AT, RT, and CT, respectively (<italic toggle="yes">P</italic> = 0.10), whereas rates of dose interruption were 33%, 44%, and 70% in AT, RT, and CT, respectively (<italic toggle="yes">P</italic> = 0.05). The most common specified reason for dose modification was arthralgia (<italic toggle="yes">Table</italic>
            <xref rid="jcsm12828-supitem-0001" ref-type="supplementary-material">S3</xref>). Arthralgia events were more common in RT‐containing exercise regimens, specifically 65% and 60% in RT and CT groups, respectively, compared with 13% in AT and AC groups (<italic toggle="yes">P</italic> &lt; 0.001; <italic toggle="yes">Table</italic>
            <xref rid="jcsm12828-supitem-0001" ref-type="supplementary-material">S4</xref>). No serious adverse events were observed during CPET procedures or any exercise training sessions.</p>
          <table-wrap position="float" id="jcsm12828-tbl-0003" content-type="Table" orientation="portrait">
            <label>Table 3</label>
            <caption>
              <p>Treatment tolerability</p>
            </caption>
            <table frame="hsides" rules="groups">
              <col align="left" span="1" />
              <col align="left" span="1" />
              <col align="left" span="1" />
              <col align="left" span="1" />
              <col align="left" span="1" />
              <col align="left" span="1" />
              <col align="char" char="." span="1" />
              <thead valign="bottom">
                <tr style="border-bottom:solid 1px #000000">
                  <th align="left" valign="bottom" rowspan="1" colspan="1">Variable</th>
                  <th align="center" valign="bottom" rowspan="1" colspan="1">All (<italic toggle="no">n</italic> = 90)</th>
                  <th align="center" valign="bottom" rowspan="1" colspan="1">AT (<italic toggle="no">n</italic> = 24)</th>
                  <th align="center" valign="bottom" rowspan="1" colspan="1">RT (<italic toggle="no">n</italic> = 23)</th>
                  <th align="center" valign="bottom" rowspan="1" colspan="1">CT (<italic toggle="no">n</italic> = 20)</th>
                  <th align="center" valign="bottom" rowspan="1" colspan="1">AC (<italic toggle="no">n</italic> = 23)</th>
                  <th align="center" valign="bottom" rowspan="1" colspan="1">
                    <italic toggle="no">P</italic>
                  </th>
                </tr>
              </thead>
              <tbody valign="top">
                <tr>
                  <td align="left" valign="top" rowspan="1" colspan="1">Lost to follow‐up, no. (%)<xref rid="jcsm12828-note-0010" ref-type="table-fn">
                      <sup>a</sup>
                    </xref>
                  </td>
                  <td align="left" valign="top" rowspan="1" colspan="1">9 (10)</td>
                  <td align="left" valign="top" rowspan="1" colspan="1">1 (4)</td>
                  <td align="left" valign="top" rowspan="1" colspan="1">3 (13)</td>
                  <td align="left" valign="top" rowspan="1" colspan="1">2 (10)</td>
                  <td align="left" valign="top" rowspan="1" colspan="1">3 (13)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.73</td>
                </tr>
                <tr>
                  <td align="left" valign="top" rowspan="1" colspan="1">Attendance, %, mean ± SD<xref rid="jcsm12828-note-0010" ref-type="table-fn">
                      <sup>a</sup>
                    </xref>
                  </td>
                  <td align="left" valign="top" rowspan="1" colspan="1">79 ± 27</td>
                  <td align="left" valign="top" rowspan="1" colspan="1">86 ± 19</td>
                  <td align="left" valign="top" rowspan="1" colspan="1">77 ± 32</td>
                  <td align="left" valign="top" rowspan="1" colspan="1">75 ± 31</td>
                  <td align="left" valign="top" rowspan="1" colspan="1">76 ± 24</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.35</td>
                </tr>
                <tr>
                  <td align="left" valign="top" rowspan="1" colspan="1">Permanent discontinuation, no. (%)<xref rid="jcsm12828-note-0011" ref-type="table-fn">
                      <sup>b</sup>
                    </xref>
                  </td>
                  <td align="left" valign="top" rowspan="1" colspan="1">16 (18)</td>
                  <td align="left" valign="top" rowspan="1" colspan="1">1 (4)</td>
                  <td align="left" valign="top" rowspan="1" colspan="1">5 (22)</td>
                  <td align="left" valign="top" rowspan="1" colspan="1">5 (25)</td>
                  <td align="left" valign="top" rowspan="1" colspan="1">5 (22)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.10</td>
                </tr>
                <tr>
                  <td align="left" valign="top" rowspan="1" colspan="1">Dose interruption, no. (%)<xref rid="jcsm12828-note-0011" ref-type="table-fn">
                      <sup>b</sup>
                    </xref>
                  </td>
                  <td align="left" valign="top" rowspan="1" colspan="1">32 (36)</td>
                  <td align="left" valign="top" rowspan="1" colspan="1">8 (33)</td>
                  <td align="left" valign="top" rowspan="1" colspan="1">10 (44)</td>
                  <td align="left" valign="top" rowspan="1" colspan="1">14 (70)</td>
                  <td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.05</td>
                </tr>
                <tr>
                  <td align="left" valign="top" rowspan="1" colspan="1">Dose modification, no. (%)<xref rid="jcsm12828-note-0011" ref-type="table-fn">
                      <sup>b</sup>
                    </xref>
                  </td>
                  <td align="left" valign="top" rowspan="1" colspan="1">52 (58)</td>
                  <td align="left" valign="top" rowspan="1" colspan="1">16 (67)</td>
                  <td align="left" valign="top" rowspan="1" colspan="1">18 (78)</td>
                  <td align="left" valign="top" rowspan="1" colspan="1">18 (90)</td>
                  <td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.17</td>
                </tr>
                <tr>
                  <td align="left" valign="top" rowspan="1" colspan="1">Pretreatment dose modification, no. (%)<xref rid="jcsm12828-note-0011" ref-type="table-fn">
                      <sup>b</sup>
                    </xref>
                  </td>
                  <td align="left" valign="top" rowspan="1" colspan="1">40 (44)</td>
                  <td align="left" valign="top" rowspan="1" colspan="1">5 (21)</td>
                  <td align="left" valign="top" rowspan="1" colspan="1">18 (78)</td>
                  <td align="left" valign="top" rowspan="1" colspan="1">17 (85)</td>
                  <td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                </tr>
                <tr>
                  <td align="left" valign="top" rowspan="1" colspan="1">Early session termination, no. (%)<xref rid="jcsm12828-note-0011" ref-type="table-fn">
                      <sup>b</sup>
                    </xref>
                  </td>
                  <td align="left" valign="top" rowspan="1" colspan="1">25 (28)</td>
                  <td align="left" valign="top" rowspan="1" colspan="1">12 (50)</td>
                  <td align="left" valign="top" rowspan="1" colspan="1">—</td>
                  <td align="left" valign="top" rowspan="1" colspan="1">13 (65)</td>
                  <td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td>
                  <td align="char" valign="top" rowspan="1" colspan="1">0.32</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot id="jcsm12828-ntgp-0004">
              <fn id="jcsm12828-note-0008">
                <p>AC, attention control; AT, aerobic training; CT, combination training; RT, resistance training; SD, standard deviation.</p>
              </fn>
              <fn id="jcsm12828-note-0009">
                <p>
                  <italic toggle="yes">Lost to follow‐up</italic> indicates lack of completion of follow‐up assessments at post‐intervention; <italic toggle="yes">attendance</italic> indicates ratio of total number of attended to planned treatments; <italic toggle="yes">permanent discontinuation</italic> indicates permanent discontinuation of treatment prior to Week 16; <italic toggle="yes">treatment interruption</italic> indicates missing ≥3 consecutive sessions; <italic toggle="yes">dose modification</italic> indicates ≥10% of sessions requiring modification (reduction/escalation) of intensity or duration; <italic toggle="yes">pretreatment dose modification</italic> indicates reduction of pretreatment session intensity; <italic toggle="yes">early session termination</italic> indicates early termination of planned session duration; <italic toggle="yes">relative dose intensity</italic> indicates the ratio of total ‘completed’ to total ‘planned’ cumulative dose. All variables are collectively counted as one entity in the same patient unless otherwise indicated.</p>
              </fn>
              <fn id="jcsm12828-note-0010">
                <label>
                  <sup>a</sup>
                </label>
                <p>
                  <italic toggle="yes">P</italic> values obtained from Fisher's exact test or Kruskal–Wallis test for differences across all groups.</p>
              </fn>
              <fn id="jcsm12828-note-0011">
                <label>
                  <sup>b</sup>
                </label>
                <p>
                  <italic toggle="yes">P</italic> values obtained from Fisher's exact test, Kruskal–Wallis test, or <italic toggle="yes">χ</italic>
                  <sup>2</sup> test for AT vs. RT vs. CT.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec sec-type="discussion" id="jcsm12828-sec-0014">
        <title>Discussion</title>
        <p>In this trial involving lung cancer survivors with poor CRF, we evaluated the effects and tolerability of three different exercise regimens relative to AC on CRF. Our results failed to support the primary hypothesis that CT would confer the largest improvements in CRF. AT and CT both lead to significant improvements in VO<sub>2</sub>peak in lung cancer survivors compared with AC. Single‐modality RT was poorly tolerated and did not augment CRF but did improve maximal strength and body composition. Our findings should be interpreted with caution given that the planned total accrual goal was not achieved, increasing the risk of type 1 and type 2 errors. Our results are therefore exploratory and should be considered hypothesis generating.</p>
        <p>The present trial is the first to evaluate exercise therapy in longer‐term lung cancer survivors, with most prior studies conducted in the immediate post‐surgical period. For instance, Edvardsen <italic toggle="yes">et al</italic>.<xref rid="jcsm12828-bib-0031" ref-type="bibr">
            <sup>31</sup>
          </xref> reported that supervised CT thrice weekly for 20 weeks was associated with a 4.1 mL O<sub>2</sub>·kg<sup>−1</sup>·min<sup>−1</sup> increase in VO<sub>2</sub>peak compared with a 0.9 mL O<sub>2</sub>·kg<sup>−1</sup>·min<sup>−1</sup> increase in the control group in 61 lung cancer patients 4–6 weeks following pulmonary resection. A subsequent meta‐analysis including four RCTs (representing 135 patients; mean sample size, <italic toggle="yes">n</italic> = 57 per study)<xref rid="jcsm12828-bib-0032" ref-type="bibr">
            <sup>32</sup>
          </xref> reported that exercise training increased VO<sub>2</sub>peak, on average, by 2.97 mL O<sub>2</sub>·kg<sup>−1</sup>·min<sup>−1</sup> compared with control. A meta‐analysis of 16 RCTs (representing 779 patients) in patients with COPD reported similar findings.<xref rid="jcsm12828-bib-0033" ref-type="bibr">
            <sup>33</sup>
          </xref> Several factors may contribute to the smaller effects of exercise therapy on CRF observed in the present trial compared with prior work [e.g. one CPET at baseline, setting (immediate vs. &gt;1 year after surgery), and non‐intention‐to‐treat analyses]. Perhaps the most important of these is the conduct of two pre‐randomization CPETs to minimize learning effects; all prior studies have conducted only one pre‐randomization CPET.<xref rid="jcsm12828-bib-0034" ref-type="bibr">
            <sup>34</sup>
          </xref> The magnitude of improvement in VO<sub>2</sub>peak across the two CPETs is consistent with our previous observations in other cancer settings<xref rid="jcsm12828-bib-0034" ref-type="bibr">
            <sup>34</sup>
          </xref>, <xref rid="jcsm12828-bib-0035" ref-type="bibr">
            <sup>35</sup>
          </xref> and indicates that learning effects may contribute to the reported magnitude of CRF improvement in prior exercise‐oncology trials.<xref rid="jcsm12828-bib-0033" ref-type="bibr">
            <sup>33</sup>
          </xref>, <xref rid="jcsm12828-bib-0034" ref-type="bibr">
            <sup>34</sup>
          </xref>
        </p>
        <p>Our trial is also the first to conduct a four‐arm trial evaluating the effects of single‐modality AT, RT, or both in comparison with usual care in any respiratory disease. The lack of larger CRF improvement with CT (compared with usual care) vs. the effects of single‐modality AT are similar to those previously reported in at least three exercise RCTs in COPD.<xref rid="jcsm12828-bib-0036" ref-type="bibr">
            <sup>36</sup>
          </xref>, <xref rid="jcsm12828-bib-0037" ref-type="bibr">
            <sup>37</sup>
          </xref>, <xref rid="jcsm12828-bib-0038" ref-type="bibr">
            <sup>38</sup>
          </xref> Further, AT had several advantages over CT including a higher RDI and requiring 30–60 min·week<sup>−1</sup> less time compared with CT. These factors support AT as the preferred modality to target impaired CRF in post‐treatment lung cancer survivors. Nevertheless, the notion that the single‐modality AT prescription tested in this trial is the ‘optimal’ exercise prescription to improve CRF in lung cancer survivors is likely imprudent.<xref rid="jcsm12828-bib-0039" ref-type="bibr">
            <sup>39</sup>
          </xref> Indeed, findings of the present trial corroborate our prior work in various oncology settings demonstrating that CRF response to exercise therapy prescribed at standard doses not only displays considerable heterogeneity but also more importantly confers relatively modest CRF improvements for most patients.<xref rid="jcsm12828-bib-0022" ref-type="bibr">
            <sup>22</sup>
          </xref>, <xref rid="jcsm12828-bib-0040" ref-type="bibr">
            <sup>40</sup>
          </xref> As a potential alternative approach, we posit that stratification of patients with a common but heterogeneous condition into homogeneous subgroups will guide targeted exercise therapy that vary in the configuration of basic exercise prescription parameters (e.g. modality, intensity, length, and sequence) to augment CRF response.<xref rid="jcsm12828-bib-0039" ref-type="bibr">
            <sup>39</sup>
          </xref>
        </p>
        <p>Three additional findings of the present trial are also noteworthy. First, none of the three exercise regimens were associated with improvements in any PROs in comparison with AC. Meta‐analyses and systematic reviews conclude that exercise therapy confers significant improvements in several PROs in cancer survivors.<xref rid="jcsm12828-bib-0041" ref-type="bibr">
            <sup>41</sup>
          </xref> Prior work, however, has classically compared exercise therapy to a non‐intervention control group.<xref rid="jcsm12828-bib-0034" ref-type="bibr">
            <sup>34</sup>
          </xref> Thus, whether the reported findings reflected an exercise‐specific effect or were a consequence of social interaction inherent to supervised exercise therapy interventions is unclear. In corroboration of our prior work also employing AC groups,<xref rid="jcsm12828-bib-0022" ref-type="bibr">
            <sup>22</sup>
          </xref>, <xref rid="jcsm12828-bib-0040" ref-type="bibr">
            <sup>40</sup>
          </xref> social interaction appears to contribute significantly to the reported favourable effects of exercise on PROs in the oncology setting. Second, despite no change in CRF, RT‐containing regimens improved maximal strength and body composition compared with AT and AC. These findings support the notion that exercise therapy should be designed to target the primary endpoint of interest.<xref rid="jcsm12828-bib-0039" ref-type="bibr">
            <sup>39</sup>
          </xref> For instance, in view of prior work indicating that RT results in favourable changes in muscle function and lean mass in lung cancer patients,<xref rid="jcsm12828-bib-0031" ref-type="bibr">
            <sup>31</sup>
          </xref>, <xref rid="jcsm12828-bib-0042" ref-type="bibr">
            <sup>42</sup>
          </xref>, <xref rid="jcsm12828-bib-0043" ref-type="bibr">
            <sup>43</sup>
          </xref> RT may be the most appropriate intervention for patients with or at high risk of cachexia or sarcopenia.<xref rid="jcsm12828-bib-0044" ref-type="bibr">
            <sup>44</sup>
          </xref>
        </p>
        <p>Finally, comprehensive evaluation of exercise therapy safety and tolerability in the present trial is novel and important. Evaluation of tolerability in prior exercise‐oncology trials is limited to reporting of LTF and attendance.<xref rid="jcsm12828-bib-0034" ref-type="bibr">
            <sup>34</sup>
          </xref> However, these metrics provide limited insight and could lead to erroneous conclusions regarding exercise tolerability in a given setting.<xref rid="jcsm12828-bib-0022" ref-type="bibr">
            <sup>22</sup>
          </xref> As illustrated in the present study, rates of LTF and attendance were within a range considered acceptable in exercise trials, yet more detailed metrics adapted from drug trials (e.g. RDI) reveal that AT was well tolerated whereas RT‐containing regimens were not, primarily due to arthralgia, fatigue, and other non‐specific reasons. To our knowledge, only one trial in the oncology setting has evaluated RT tolerability using ‘drug trial’ metrics. Fairman <italic toggle="yes">et al</italic>.<xref rid="jcsm12828-bib-0045" ref-type="bibr">
            <sup>45</sup>
          </xref> reported dose interruption and modification rates of 51% and 85% in 47 men with advanced prostate cancer receiving single‐modality RT (three times weekly for 12 weeks). Further investigation of the tolerability‐to‐benefit ratio of RT‐containing exercise regimens is required, particularly in older, more frail cancer populations.</p>
        <sec id="jcsm12828-sec-0015">
          <title>Limitations</title>
          <p>The most important limitation is that the planned accrual was not achieved. This significantly impacts interpretability of trial results. Generalizability of our findings may be limited by the low participation rate. The reasons for non‐participation (and therefore slow accrual) were mainly related to the inconvenience (e.g. travel distance) of facility‐based supervised exercise sessions. This approach was selected to maximize exercise treatment fidelity and safety/tolerability. Clearly, however, design and testing of ‘site‐less’ telemedicine solutions that enable exercise sessions and potentially other study procedures to be conducted remotely may address major barriers to the rigorous conduct of exercise training investigations in clinical populations.<xref rid="jcsm12828-bib-0046" ref-type="bibr">
              <sup>46</sup>
            </xref>, <xref rid="jcsm12828-bib-0047" ref-type="bibr">
              <sup>47</sup>
            </xref> Second, our findings are limited to unfit lung cancer survivors and do not generalize to patients with normal CRF with different exercise training tolerability and response. Third, we tested the effects of intensely monitored exercise regimens that were carefully individualized, quantified, and sequenced; thus, the feasibility, safety, and efficacy of exercise regimens will likely differ when implemented under different conditions. Other limitations include the short length of intervention.</p>
        </sec>
      </sec>
      <sec sec-type="conclusions" id="jcsm12828-sec-0016">
        <title>Conclusions</title>
        <p>In the context of a smaller than planned sample size, AT and CT significantly improved VO<sub>2</sub>peak in lung cancer survivors; however, the tolerability‐to‐benefit ratio was superior for AT and hence may be the preferred modality to target impaired CRF in post‐treatment lung cancer survivors.</p>
      </sec>
      <sec id="jcsm12828-sec-0020">
        <title>Author contributions</title>
        <p>L.W.J. obtained the funding. L.W.J. coordinated the study and is the guarantor. L.W.J., J.E.H., P.S.D., and N.D.E. designed the study. J.M.S., C.C., J.N.H., K.J.S., T.N., E.E., M.G.M., and L.W.J. collected the data. S.M.T. and J.E.H. analysed the data. L.W.J. wrote the first substantial draft of the article and is the guarantor. All authors critically revised the manuscript. All authors read and approved the final manuscript. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.</p>
      </sec>
      <sec sec-type="COI-statement" id="jcsm12828-sec-0019">
        <title>Conflict of interest</title>
        <p>L.W.J. has stock ownership in Pacylex, Inc. Other authors report no conflict of interest.</p>
      </sec>
      <sec sec-type="supplementary-material">
        <title>Supporting information</title>
        <supplementary-material id="jcsm12828-supitem-0001" position="float" content-type="local-data" orientation="portrait">
          <caption>
            <p>
              <bold>Table S1.</bold> Aerobic Training Dose Modification Guidelines.</p>
            <p>
              <bold>Table S2</bold>. Comparison of Exercise Treatment Modalities on Primary and Secondary End points.</p>
            <p>
              <bold>Table S3</bold>. Reasons for Exercise Dose Modifications.</p>
            <p>
              <bold>Table S4</bold>. Adverse Events.</p>
            <p>
              <bold>Figure S1</bold>. Comparison of VO<sub>2</sub>peak Between the Two Cardiopulmonary Exercise Tests Conducted at Pre‐Randomization.</p>
            <p>Supplementary References.</p>
            <p>Supplementary Methods</p>
          </caption>
          <media ns0:href="JCSM-12-1456-s001.docx" position="float" orientation="portrait">
            <caption>
              <p>Click here for additional data file.</p>
            </caption>
          </media>
        </supplementary-material>
      </sec>
    </body>
  </article>
</pmc-articleset>